Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo ?

29 Sept 2009

Abstract excerpt

PURPOSE: Poly(ADP-ribose) polymerase (PARP) plays an important role in DNA repair, and PARP inhibitors can enhance the activity of DNA-damaging agents in vitro and in vivo. AG014699 is a potent PARP inhibitor in phase II clinical development. However, the range of therapeutics with which AG014699 could interact via a DNA-repair based mechanism is limited. We aimed to investigate a novel, vascular-based activity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to PARP inhibition in cancer therapy
Share to Sirtuins and Resveratrol in Medicine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19789326
DOI: 10.1158/1078-0432.ccr-09-0398

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo ?PMID 19789326Read ↗

Hydralazine as a Repurposed Epigenetic and Metabolic Modulator in Glioblastoma: Promise, Pitfalls, and Future DirectionsSemantic proximity Read ↗

Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in TumorsSemantic proximity Read ↗

Vascular dysfunction is at the onset of oxaliplatin-induced peripheral neuropathy symptoms in miceSemantic proximity Read ↗

Vasohibins in Health and Disease: From Angiogenesis to Tumorigenesis, Multiorgan Dysfunction, and Brain–Heart RemodelingSemantic proximity Read ↗

Systemic CYP3A inhibition by ritonavir enables selective targeting of hypoxic tumour cells by prodrugs of DNA-PK inhibitorsSemantic proximity Read ↗

Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injurySemantic proximity Read ↗

NF-kappaB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA.Semantic proximity Read ↗

Vascular Disruption in Combination with mTOR Inhibition in Renal Cell CarcinomaSemantic proximity Read ↗

Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts.Semantic proximity Read ↗

Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited.Semantic proximity Read ↗

Hypoxia-Inducible Factor-1 Target Genes as Indicators of Tumor Vessel Response to Vascular Endothelial Growth Factor InhibitionSemantic proximity Read ↗

Inhibition of Polyamine Uptake Potentiates the Anti-Proliferative Effect of Polyamine Synthesis Inhibition and Preserves the Contractile Phenotype of Vascular Smooth Muscle Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.